Latest immunosuppression Stories
Oxford University scientists have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation.
- Result seen across stable and de novo kidney transplant patients - HORSHOLM, Denmark, June 30, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily
New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV.
Decision Alleviates Concerns Over Potential for Organ Rejections, Preserves Physician Discretion Over Patient Care WASHINGTON, March 13, 2014 /PRNewswire-USNewswire/ -- Kidney Care
HORSHOLM, Denmark, March 6, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that John Weinberg, M.D., currently chief commercial officer of Veloxis, has been promoted to
HORSHOLM, Denmark, Jan.
More than 260,000 Americans are alive today thanks to transplant operations that have replaced their failing kidneys, hearts, lungs or livers with healthy organs donated by volunteers or accident victims.
Nearly 17,000 kidney transplants take place each year in the United States.